Loading...

We've got a brand new version of Simply Wall St! Try it out

Bio-Techne

Nasdaq:TECH
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TECH
Nasdaq
$8B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
TECH Share Price and Events
7 Day Returns
4.1%
NasdaqGS:TECH
4.8%
US Life Sciences
0.7%
US Market
1 Year Returns
36.3%
NasdaqGS:TECH
18.7%
US Life Sciences
13.7%
US Market
TECH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bio-Techne (TECH) 4.1% 5.6% 9.8% 36.3% 102.1% 129.9%
US Life Sciences 4.8% 6.7% 5.4% 18.7% 93.2% 117.8%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • TECH outperformed the Life Sciences industry which returned 18.7% over the past year.
  • TECH outperformed the Market in United States of America which returned 13.7% over the past year.
Price Volatility
TECH
Industry
5yr Volatility vs Market

Value

 Is Bio-Techne undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bio-Techne to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bio-Techne.

NasdaqGS:TECH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:TECH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.024 (1 + (1- 21%) (7.21%))
1.055
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.055 * 5.96%)
9.02%

Discounted Cash Flow Calculation for NasdaqGS:TECH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bio-Techne is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGS:TECH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.02%)
2020 149.06 Analyst x2 136.73
2021 220.39 Analyst x2 185.44
2022 262.09 Analyst x2 202.29
2023 293.44 Est @ 11.96% 207.75
2024 320.41 Est @ 9.19% 208.08
2025 343.65 Est @ 7.25% 204.72
2026 363.91 Est @ 5.9% 198.86
2027 381.91 Est @ 4.95% 191.43
2028 398.26 Est @ 4.28% 183.11
2029 413.46 Est @ 3.82% 174.38
Present value of next 10 years cash flows $1,892.00
NasdaqGS:TECH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $413.46 × (1 + 2.73%) ÷ (9.02% – 2.73%)
$6,756.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,756.02 ÷ (1 + 9.02%)10
$2,849.38
NasdaqGS:TECH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,892.00 + $2,849.38
$4,741.38
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,741.38 / 38.11
$124.41
NasdaqGS:TECH Discount to Share Price
Calculation Result
Value per share (USD) From above. $124.41
Current discount Discount to share price of $211.42
= -1 x ($211.42 - $124.41) / $124.41
-69.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Bio-Techne is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bio-Techne's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bio-Techne's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:TECH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $2.46
NasdaqGS:TECH Share Price ** NasdaqGS (2019-11-18) in USD $211.42
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 33.43x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bio-Techne.

NasdaqGS:TECH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TECH Share Price ÷ EPS (both in USD)

= 211.42 ÷ 2.46

86.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Techne is overvalued based on earnings compared to the US Life Sciences industry average.
  • Bio-Techne is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Bio-Techne's expected growth come at a high price?
Raw Data
NasdaqGS:TECH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 86.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
25.9%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.74x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

NasdaqGS:TECH PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 86.11x ÷ 25.9%

3.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Techne is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Bio-Techne's assets?
Raw Data
NasdaqGS:TECH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $30.83
NasdaqGS:TECH Share Price * NasdaqGS (2019-11-18) in USD $211.42
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 5.07x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqGS:TECH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TECH Share Price ÷ Book Value per Share (both in USD)

= 211.42 ÷ 30.83

6.86x

* Primary Listing of Bio-Techne.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Techne is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Bio-Techne's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Bio-Techne has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bio-Techne expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bio-Techne expected to grow at an attractive rate?
  • Bio-Techne's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Bio-Techne's earnings growth is expected to exceed the United States of America market average.
  • Bio-Techne's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:TECH Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:TECH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 25.9%
NasdaqGS:TECH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 10.2%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.3%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:TECH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:TECH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 965 289 179 3
2021-06-30 880 251 146 6
2020-06-30 791 215 107 6
2019-11-18
NasdaqGS:TECH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 734 183 93
2019-06-30 714 182 96
2019-03-31 703 191 121
2018-12-31 682 173 96
2018-09-30 661 165 128
2018-06-30 643 170 126
2018-03-31 619 156 112
2017-12-31 599 160 114
2017-09-30 577 162 73
2017-06-30 563 144 76
2017-03-31 541 129 74
2016-12-31 528 141 82

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bio-Techne's earnings are expected to grow significantly at over 20% yearly.
  • Bio-Techne's revenue is expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:TECH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Bio-Techne Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TECH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 4.43 4.75 4.24 3.00
2021-06-30 3.63 3.96 3.48 4.00
2020-06-30 2.72 2.83 2.47 4.00
2019-11-18
NasdaqGS:TECH Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 2.46
2019-06-30 2.54
2019-03-31 3.22
2018-12-31 2.56
2018-09-30 3.40
2018-06-30 3.36
2018-03-31 2.99
2017-12-31 3.06
2017-09-30 1.96
2017-06-30 2.04
2017-03-31 1.99
2016-12-31 2.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bio-Techne is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Bio-Techne's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bio-Techne has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bio-Techne performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bio-Techne's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bio-Techne's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Bio-Techne's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Bio-Techne's 1-year earnings growth is negative, it can't be compared to the US Life Sciences industry average.
Earnings and Revenue History
Bio-Techne's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bio-Techne Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TECH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 734.28 92.97 264.46 63.70
2019-06-30 714.01 95.97 262.08 62.41
2019-03-31 702.60 121.21 257.13 60.13
2018-12-31 681.71 96.31 244.13 58.47
2018-09-30 661.35 127.58 231.70 56.57
2018-06-30 642.99 126.04 215.83 55.33
2018-03-31 619.32 111.97 193.78 55.05
2017-12-31 599.38 114.39 187.22 54.93
2017-09-30 577.04 73.04 183.47 54.30
2017-06-30 563.00 76.02 174.65 53.51
2017-03-31 541.19 74.06 169.79 51.46
2016-12-31 528.12 82.20 158.28 48.93
2016-09-30 517.22 100.60 145.32 46.63
2016-06-30 499.02 104.42 138.12 45.19
2016-03-31 481.92 105.18 130.42 44.36
2015-12-31 465.11 99.18 125.27 43.98
2015-09-30 456.15 106.54 121.29 43.03
2015-06-30 452.25 107.74 114.88 40.85
2015-03-31 426.61 108.23 100.80 37.68
2014-12-31 408.00 115.58 86.32 34.50
2014-09-30 380.07 107.43 71.31 32.39
2014-06-30 357.76 110.95 59.82 30.95
2014-03-31 344.62 112.54 54.20 30.48
2013-12-31 330.05 114.01 49.91 30.03
2013-09-30 321.12 114.32 45.94 29.51
2013-06-30 310.58 112.56 42.78 29.26
2013-03-31 309.78 111.39 41.63 29.36
2012-12-31 312.41 110.03 41.54 29.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Bio-Techne has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Bio-Techne used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • Bio-Techne's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Bio-Techne's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bio-Techne has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bio-Techne's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bio-Techne's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bio-Techne is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bio-Techne's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Bio-Techne's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bio-Techne Company Filings, last reported 1 month ago.

NasdaqGS:TECH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,174.22 499.17 158.41
2019-06-30 1,165.59 517.62 166.03
2019-03-31 1,146.27 529.83 178.79
2018-12-31 1,096.43 550.50 156.53
2018-09-30 1,109.47 561.47 163.72
2018-06-30 1,079.06 339.00 181.75
2018-03-31 1,058.29 392.50 176.43
2017-12-31 997.82 362.50 162.39
2017-09-30 959.81 337.50 122.73
2017-06-30 949.63 343.77 157.71
2017-03-31 907.93 358.22 113.62
2016-12-31 890.57 347.25 115.50
2016-09-30 895.40 347.23 121.97
2016-06-30 879.28 95.26 95.84
2016-03-31 852.96 161.62 84.59
2015-12-31 856.34 166.58 113.92
2015-09-30 837.95 168.24 87.27
2015-06-30 846.94 77.02 110.92
2015-03-31 820.07 155.02 159.95
2014-12-31 820.68 157.02 139.94
2014-09-30 793.41 124.95 130.81
2014-06-30 795.27 12.95 363.35
2014-03-31 777.04 0.00 220.13
2013-12-31 748.53 0.00 186.86
2013-09-30 726.76 0.00 184.70
2013-06-30 737.54 0.00 332.94
2013-03-31 719.51 0.00 312.88
2012-12-31 694.57 0.00 286.10
  • Bio-Techne's level of debt (42.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (15.8% vs 42.5% today).
  • Debt is well covered by operating cash flow (36.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 7.5x coverage).
X
Financial health checks
We assess Bio-Techne's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bio-Techne has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bio-Techne's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.61%
Current annual income from Bio-Techne dividends. Estimated to be 0.61% next year.
If you bought $2,000 of Bio-Techne shares you are expected to receive $12 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Bio-Techne's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.42%).
  • Bio-Techne's dividend is below the markets top 25% of dividend payers in United States of America (3.65%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:TECH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:TECH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 1.30 2.00
2021-06-30 1.31 3.00
2020-06-30 1.29 3.00
2019-11-18
NasdaqGS:TECH Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-10-29 1.280 0.620
2019-08-06 1.280 0.652
2019-04-30 1.280 0.622
2019-02-07 1.280 0.658
2019-02-05 1.280 0.686
2018-10-30 1.280 0.812
2018-08-07 1.280 0.681
2018-05-02 1.280 0.824
2018-02-08 1.280 0.878
2017-10-31 1.280 0.966
2017-08-10 1.280 1.052
2017-05-10 1.280 1.119
2017-02-09 1.280 1.223
2016-10-31 1.280 1.241
2016-08-17 1.280 1.197
2016-05-10 1.280 1.161
2016-05-03 1.280 1.268
2016-02-02 1.280 1.404
2015-10-29 1.280 1.454
2015-08-06 1.280 1.333
2015-05-05 1.280 1.260
2015-02-03 1.280 1.312
2014-10-30 1.280 1.395
2014-08-11 1.240 1.325
2014-04-28 1.240 1.369
2014-02-04 1.240 1.420
2013-10-31 1.240 1.381
2013-08-06 1.200 1.507
2013-04-30 1.200 1.733
2013-02-05 1.200 1.794
2012-10-25 1.200 1.723
2012-07-31 1.120 1.603
2012-05-01 1.120 1.596
2012-01-31 1.120 1.630
2011-10-27 1.120 1.658
2011-08-02 1.080 1.530
2011-05-10 1.080 1.347
2011-05-03 1.080 1.371
2011-02-01 1.080 1.501
2010-10-28 1.080 1.690
2010-08-03 1.040 1.707
2010-05-05 1.040 1.751
2010-02-02 1.040 1.621
2009-10-29 1.040 1.550
2009-08-04 1.000 1.603
2009-04-28 1.000 1.629
2009-02-03 1.000 1.902

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Techne is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Bio-Techne is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Bio-Techne's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Bio-Techne's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • No need to calculate the sustainability of Bio-Techne's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Bio-Techne's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bio-Techne afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bio-Techne has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bio-Techne's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chuck Kummeth
COMPENSATION $11,011,139
AGE 59
TENURE AS CEO 6.6 years
CEO Bio

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. Mr. Kummeth served as a Director of Avantor, Inc. since 2016 until April 2019. Mr. Kummeth served as the President of the Global Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific Inc. since September 2011 until March 2013. Mr. Kummeth has significant industry experience in the areas of serving science, innovative technologies, software and laboratory operations. He has over 30 years of global business and life sciences experience. He served as an Executive Officer of United Kingdom for Ireland Region at 3M Company (Alternate Name - 3M Corporation). He served as the President of the Laboratory Consumables Division of Thermo Fisher Scientific from 2009 to September 2011. He has worked in the industrial, semiconductor, scientific and healthcare industries for 30 years, including 24 years at 3M. His initial work was on data storage devices, an early project was helping Apple with peripheral solutions for the first Macintosh computer. Mr. Kummeth managed 3M's International Mergers and Acquisitions Group and served as Vice President of the Electronics Materials and Medical Products Divisions from 2006 to 2008. He previously served as President of the Medical Product Division of 3M, a Delaware corporation, beginning in 2006. From 2004 to 2006, He spent three years in Europe as the Head of 3M's industrial businesses and also served as the Managing Director of 3M for the UK and Ireland. He has been a Director of Bio-Techne Corporation since April 1, 2013. Mr. Kummeth has served on the board of Avantor, Inc., a private global life sciences company since May 2016. He has been a Director of Gentherm Incorporated since August 1, 2018. He served on the board of BSN Medical Inc., a private global medical device company, from March 2013 to July 2016. He has extensive executive management experience and expertise leading the growth of biotechnology companies. He was an Independent Director of Sparton Corporation since November 11, 2011 until March 4, 2019. He served as a Director at NuSil Technology LLC since March 2016. He has a BS in Electrical Engineering, an MS in Software Design and Engineering and an MBA from the Carlson School of Business at the University of Minnesota in 1993. He received a Master of Science in Computer Science from the University of St. Thomas in 1989. Mr. Kummeth holds a BS in Electrical Engineering of the University of North Dakota in 1983.

CEO Compensation
  • Chuck's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chuck's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Bio-Techne management team in years:

5.3
Average Tenure
58
Average Age
  • The average tenure for the Bio-Techne management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chuck Kummeth

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
59
TENURE
6.6 yrs

Jim Hippel

TITLE
Senior VP of Finance & CFO
COMPENSATION
$3M
AGE
48
TENURE
5.6 yrs

Brenda Furlow

TITLE
Senior VP
COMPENSATION
$1M
AGE
61
TENURE
5.3 yrs

Dave Eansor

TITLE
President of Protein Sciences Segment
COMPENSATION
$2M
AGE
58
TENURE
5.3 yrs

Kim Kelderman

TITLE
President of Diagnostics & Genomics
COMPENSATION
$2M
AGE
52
TENURE
1.6 yrs

Gerry Andros

TITLE
Vice President of Sales and Marketing

Frank Mortari

TITLE
Vice President of Corporate Development

Luca Cicchetti

TITLE
Managing Director
TENURE
3.3 yrs

David Clair

TITLE
Senior Director of Corporate Development
Board of Directors Tenure

Average tenure and age of the Bio-Techne board of directors in years:

6.8
Average Tenure
65
Average Age
  • The tenure for the Bio-Techne board of directors is about average.
Board of Directors

Bob Baumgartner

TITLE
Independent Chairman of the Board
COMPENSATION
$318K
AGE
63
TENURE
7 yrs

Chuck Kummeth

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
59
TENURE
6.6 yrs

Randolph Steer

TITLE
Independent Director
COMPENSATION
$271K
AGE
69
TENURE
29.8 yrs

John Higgins

TITLE
Independent Director
COMPENSATION
$278K
AGE
49
TENURE
10.5 yrs

Roel Nusse

TITLE
Independent Director
COMPENSATION
$268K
AGE
69

Harold Wiens

TITLE
Independent Director
COMPENSATION
$253K
AGE
73
TENURE
5.5 yrs

Sachdev Sidhu

TITLE
Member of Scientific Advisory Board

David Artis

TITLE
Member of Scientific Advisory Board

John Denu

TITLE
Member of Scientific Advisory Board

Joe Keegan

TITLE
Independent Director
COMPENSATION
$253K
AGE
65
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Bio-Techne individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Sep 19 Buy Charles Kummeth Individual 09. Sep 19 09. Sep 19 200 $185.00 $37,000
09. Aug 19 Buy Robert Baumgartner Individual 07. Aug 19 07. Aug 19 500 $191.06 $95,530
X
Management checks
We assess Bio-Techne's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bio-Techne has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Be Worried About Bio-Techne Corporation's (NASDAQ:TECH) 8.2% Return On Equity?

One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.082 in profit. … The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Bio-Techne: 8.2% = US$96m ÷ US$1.2b (Based on the trailing twelve months to June 2019.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Return on Equity measures a company's profitability against the profit it has kept for the business (plus any capital injections).

Simply Wall St -

The Chairman of the Board of Bio-Techne Corporation (NASDAQ:TECH), Robert Baumgartner, Just Bought 6.078288% More Shares

Check out our latest analysis for Bio-Techne The Last 12 Months Of Insider Transactions At Bio-Techne In fact, the recent purchase by Robert Baumgartner was the biggest purchase of Bio-Techne shares made by an insider individual in the last twelve months, according to our records. … NasdaqGS:TECH Recent Insider Trading, August 10th 2019 Does Bio-Techne Boast High Insider Ownership? … When combined with notable insider ownership, these factors suggest Bio-Techne insiders are well aligned, and that they may think the share price is too low.

Simply Wall St -

What Are Analysts Expecting From Bio-Techne Corporation (NASDAQ:TECH) In Next 12 Months?

Check out our latest analysis for Bio-Techne Can we expect Bio-Techne to keep growing? … To understand the overall trajectory of TECH's earnings growth over these next fews years, I've fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope. … NasdaqGS:TECH Past and Future Earnings, August 5th 2019 By 2022, TECH's earnings should reach US$194m, from current levels of US$126m, resulting in an annual growth rate of 17%.

Simply Wall St -

Can You Imagine How Chuffed Bio-Techne's (NASDAQ:TECH) Shareholders Feel About Its 119% Share Price Gain?

During five years of share price growth, Bio-Techne achieved compound earnings per share (EPS) growth of 1.0% per year. … When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. … We note that for Bio-Techne the TSR over the last 5 years was 131%, which is better than the share price return mentioned above.

Simply Wall St -

Is Bio-Techne Corporation's (NASDAQ:TECH) Growth Strong Enough To Justify Its July Share Price?

Bio-Techne is trading at price-to-earnings (PE) ratio of 65.15x, this also tells us the stock is overvalued based on current earnings compared to the Life Sciences industry average of 39.39x , and overvalued compared to the US market average ratio of 17.86x. … NasdaqGS:TECH Price Estimation Relative to Market, July 22nd 2019 After looking at TECH's value based on current earnings, we can see it seems overvalued relative to other companies in the industry. … This tells us that when we include its growth in our analysis Bio-Techne's stock can be considered overvalued , based on the fundamentals.

Simply Wall St -

Is Bio-Techne Corporation (NASDAQ:TECH) Potentially Undervalued?

Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. … TECH’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. … If you are no longer interested in Bio-Techne, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Simply Wall St -

Do Bio-Techne's (NASDAQ:TECH) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it completely lacks a track record of revenue and profit. … Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. … Of course, profit growth is one thing but it's even better if Bio-Techne is receiving high returns on equity, since that should imply it can keep growing without much need for capital.

Simply Wall St -

Did Business Growth Power Bio-Techne's (NASDAQ:TECH) Share Price Gain of 116%?

For example, the Bio-Techne Corporation (NASDAQ:TECH) share price has soared 116% in the last half decade. … Bio-Techne's earnings per share are down 3.7% per year, despite strong share price performance over five years. … By glancing at these numbers, we'd posit that the decline in earnings per share is not representative of how the business has changed over the years.

Simply Wall St -

Need To Know: Bio-Techne Corporation (NASDAQ:TECH) Insiders Have Been Selling Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … That means that an insider was selling shares at slightly below the current price (US$195). … However, while insider selling is sometimes discouraging, it's only a weak signalN

Simply Wall St -

Is Bio-Techne Corporation's (NASDAQ:TECH) Growth Strong Enough To Justify Its April Share Price?

Bio-Techne Corporation (NASDAQ:TECH) is a stock well-positioned for future growth, but many investors are wondering whether its last closing price of $199 is based on unrealistic expectations. … Let’s take a look at some key metrics to determine whether there's any value here for current and potential future investors. … One reason why investors are attracted to TECH is the high growth potential in the near future

Simply Wall St -

Company Info

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers reagent solutions, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera reagents, and cell selection technologies. This segment also provides analytical solutions, including manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. In addition, it offers various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Details
Name: Bio-Techne Corporation
TECH
Exchange: NasdaqGS
Founded: 1976
$8,057,677,941
38,112,184
Website: http://www.bio-techne.com
Address: Bio-Techne Corporation
614 McKinley Place NE,
Minneapolis,
Minnesota, 55413,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TECH Common Stock Nasdaq Global Select US USD 09. Feb 1989
DB TE1 Common Stock Deutsche Boerse AG DE EUR 09. Feb 1989
Number of employees
Current staff
Staff numbers
2,255
Bio-Techne employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 23:47
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/14
Last earnings filing: 2019/11/06
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.